Results 201 to 210 of about 52,122 (312)

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment. [PDF]

Br J Clin Pharmacol
Soeiro T, Lacroix C, Jouve É, Frauger É, Lapeyre-Mestre M, Micallef J.   +5 more
europepmc   +1 more source

Prescription of Psychotropic Drugs for Chronic Insomnia in Primary Care

Journal of Sleep Research, EarlyView.
ABSTRACT Insomnia is the most prevalent sleep disorder in adults, representing a major public health problem. Healthcare management in a specific area first requires analysing its current practices and issues. We conducted a retrospective observational study of over 100,000 patients from two large primary care databases in the public healthcare ...
Jesús Escribá‐Alepuz, Lidia Herrero‐Huertas, María García‐Gil, Estefanía Estévez‐López, Francisco Javier Puertas, Manuel de Entrambasaguas   +5 more
wiley   +1 more source

Characteristics and comorbidities of patients on opioid agonist therapy in Switzerland: A descriptive analysis of the nationwide SAMMSU cohort. [PDF]

Drug Alcohol Depend Rep
Lütolf M, Bregenzer A, Bruggmann P, Moriggia A, Scheidegger C, Hensel-Koch K, Batänjer EC, Thurnheer MC, Della Santa P, Senn O, Grischott T.   +10 more
europepmc   +1 more source

Pharmacokinetics of 2 mg/kg Bupivacaine in a Rectus Abdominis Sheath Block in Horses

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Administering large volumes of bupivacaine in the rectus abdominis sheath (RAS) block in horses could cause local anesthetic toxicity. This study aimed to evaluate the pharmacokinetics of 2 mg/kg bupivacaine in RAS blocks and the associated toxicity risk.
Daniel M. Sakai, Yushun Ishikawa, Jessica S. Y. Im, Shufan Zhang, Rachel A. Reed, Jane E. Quandt, Michele Barletta, Heather K. Knych   +7 more
wiley   +1 more source

Multimethod feasibility evaluation of smoking cessation intervention for patients receiving opioid agonist therapy. [PDF]

Pilot Feasibility Stud
Druckrey-Fiskaaen KT, Madebo T, Carlsen SL, Furulund E, Vold JH, Daltveit JT, Lid TG, Fadnes LT, ATLAS4LAR Study Group.   +8 more
europepmc   +1 more source

Influence of Tramadol on the Intravenous Pharmacokinetics of Dipyrone Active Metabolites in Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT This study aimed to compare the pharmacokinetic profile of the active dipyrone metabolites 4‐methylaminoantipyrine (MAA) and 4‐aminoantipyrine (AA) administered alone and in combination with tramadol in dogs. Nine mixed‐breed dogs, weighing 15.33 ± 2.25 kg, participated in a two‐treatment crossover design: G1 received intravenous dipyrone (25 ...
Andressa Nunes Mouta, Kathryn Nóbrega Arcoverde, Robson dos Anjos Honorato, Naftáli Silva Fernandes, Caio Vinicius Almeida de Oliveira, Glícia Cavalcante Mesquita, Yanna Deysi Bandeira Passos, Gabriel Araújo‐Silva, Valéria Veras de Paula   +8 more
wiley   +1 more source

Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey. [PDF]

Drug Alcohol Rev
Santo T, Bharat C, Rodgers C, Harrod M, Taylor S, Zahra E, Sutherland R, Peacock A, Grebely J, Hickman M, Farrell M, Degenhardt L.   +11 more
europepmc   +1 more source

Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR) in Healthy Beagles

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT This study evaluated the pharmacokinetics of an extended‐release buprenorphine formulation (Ethiqa XR) in dogs and explored potential sex differences. Twelve healthy intact beagles (6 males and 6 females) received a single subcutaneous injection of Ethiqa XR (0.2 mg/kg).
Kornelia Tiffinger, Hiroko Enomoto, Ronald E. Baynes, Laura M. Neumann, B. Duncan X. Lascelles, Masataka Enomoto   +5 more
wiley   +1 more source

Fatalities in opioid agonist treatment with long-acting injectable buprenorphine. [PDF]

Int J Legal Med
Häkkinen M, Mariottini C, Kriikku P, Ojanperä I.   +3 more
europepmc   +1 more source

Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Tapentadol is a dual mechanism analgesic utilizing both μ‐opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). This study evaluated the pharmacokinetics and pharmacodynamics of tapentadol as a potential analgesic with the goal of treating pain in horses.
Annabella D. Lynch, Khursheed R. Mama, Dan S. McKemie, Phillip H. Kass, Heather K. Knych   +4 more
wiley   +1 more source